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Abstract
The results presented herein represent our continued study based on the modification of phenolic functionality in mol-
ecules originated from natural sources by acylation. A small focused library of nineteen eugenyl esters, with four of 
which are new compounds, is reported. All compounds were subjected to in vitro antimicrobial testing. In silico studies 
were carried out calculating physico-chemical, pharmacokinetic and toxicological properties, providing more data as 
additional guidance for further research.
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1. Introduction
Natural products, especially those derived from 
plants, represent an excellent source of new bioactive com-
pounds since their structures may be used as natural phar-
macophores enabling structural derivatization.1 Phenylpro-
penes belong to a vast family of compounds called phenyl-
propanoids that are biosynthesized in plants from the ami-
no acids phenylalanine and tyrosine via shikimate pathway.2 
Phenylpropenes, such as eugenol, isoeugenol, chavicol and 
anethole are biosynthesized by flowering plants as defense 
compounds against animals and microorganisms.3 Because 
of the antimicrobial properties of phenylpropenes, as well as 
their pleasant aromas and flavors, since ancient times hu-
mans have used plant materials containing such compounds 
to preserve and flavor their food (cloves, allspice, black pep-
per, anise, fennel; all of these containing significant amounts 
of phenylpropenes) and as medicinal agents.3
Eugenol (4-allyl-2-methoxyphenol) is naturally oc-
curring in essential oils of variety of plants belonging to 
Lamiaceae, Lauraceae, Myrtaceae and Myristicaceae fami-
lies. It is one of the major constituents of clove (Syzygium 
aromaticum (L.) Merrill & Perry, Myrtaceae) oil and is 
largely used both in foods and as flavouring agent.4,5 Euge-
nol and its close analogues have several proven biological 
activities6–16 which make it useful in pharmaceutical pro-
duction. Additionally, eugenol has been described as an 
agent with dual effect: antioxidant and pro-oxidant, postu-
lating the existence of beneficial properties in both preven-
tion of cancer formation and in cancer treatment.17 Ac-
cording to previous in vitro and in vivo studies eugenol 
might function as a tumor suppressor in most cancer types 
inspected.17–20
The activity of eugenol against microorganisms is 
also well known.21,22 The mechanisms of antimicrobial ac-
tion have been documented in both bacteria and fun-
gi.21,23–25 According to a review discussing mechanisms of 
antimicrobial action of eugenol and essential oils contain-
ing eugenol, two main uses of eugenol are particularly in-
dicated: against food-decaying microorganisms and 
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against bacteria causing oral clinical conditions.21 In a re-
view published by Freires et al.26 it was concluded that due 
to its promising antimicrobial activity against streptococci, 
eugenol should be considered as an anti-cariogenic agent 
worth of further clinical testing. The mode of action of eu-
genol against microbials has been thoroughly investigated 
and reviewed by Marchese et al.21 In this paper a systemat-
ic presentation of the mechanisms against bacteria and 
fungi known so far is given. Compounds obtained by deri-
vatisation of eugenol have also been reported as antimi-
crobial agents.1,27–30 So far, the most frequently investigat-
ed eugenol derivatives in bioassays are glycosides27–30 and 
esters.31–33 Like eugenol, eugenyl esters can also represent 
compounds of promising biological properties. Several pa-
pers on isolation and/or synthesis and biological activity of 
eugenyl esters have reported wide range of activities: anti-
oxidant,9,11,13,34 anticancer,35 larvicidal,37 anti-leishmania-
sis.38 On the other hand, little data exists on antimicrobial 
activity, reporting only few compounds involved with re-
spect to the total number synthesized. Antimicrobial as-
says evaluated antibacterial activity of eugenyl esters of 
acetic, 3-methylbutanoic, pentanoic and benzoic ac-
ids,31–33 but no data related to antifungal activity of such 
derivatives was reported.
The diverse pharmacological activity of eugenol and 
eugenyl esters, scarce results on antibacterial and no re-
sults on antifungal activity of ester derivatives, have de-
termined the aim of our study. By making a modification 
of a phenolic functionality in eugenol, we have obtained a 
series of ester compounds (3a–s), performed their struc-
tural characterization, in vitro antimicrobial testing and 
in silico calculation of physico-chemical, pharmacokinet-
ic and toxicological properties. An important contribu-
tion of this study is the synthesis of four new compounds 
(3l, 3n, 3p and 3r), followed by the results obtained in 
antibacterial together with the first results ever obtained 
in an antifungal assay, and by in silico calculations. All 
together represent an important aspect to guide further 
research.
2. Materials and Methods
2. 1. Chemicals Used
All the reagents, standards and solvents used were of 
analytical reagent grade. Unless specified otherwise, all 
chemicals were purchased from Merck (Darmstadt, Ger-
many).
2. 2. General Synthetic Procedures
Acetyl, benzoyl and palmitoyl chloride (2a, 2r, 2s) 
were purchased from Sigma-Aldrich. For the preparation 
of acyl chlorides 2b–p, 2r and of eugenyl esters (Table 1, 
entries 3a–s) methods from the literature39–42 were uti-
lized and general procedures for the synthesis as reported 
in our previously published paper was followed.43 Scheme 
1 represents the synthesis of eugenyl esters.
The obtained esters of eugenol 3a–s were purified by 
column chromatography, stationary phase Silica Gel 60 
(70–230 mesh), mobile phase (hexane/diethyl ether, gradi-
ent 9:1 to 6:4). For yields see Table 1. For solid compounds 
3q, 3r and 3s melting points were determined in a Stuart 
Scientific SMP3 apparatus and are uncorrected.
Eugenyl Acetate (3a)
Chromatographic purification gave yellowish oil. 
C12H14O3 (M = 206.24); yield 96%; MS (EI): m/z (%) 206 
(M+), 164 (100), 149 (27.23), 133 (15.32), 131 (20.72), 121 
(11.81), 104 (16.72), 103 (18.52), 91 (23.22), 77 (17.02), 43 
(14.18); RI (HP5-MS): 1538; 1H NMR (500.13 MHz, 
CDCl3): δ 6.98 (1H, d, J = 8 Hz, H-6), 6.77 (2H, m, H-3 
and H-5), 6.04 (1H, m, H-9), 5.13 (2H, m, H-10), 3.85 
(3H, s, H-7), 3.41 (2H, d, J = 6 Hz, H-8), 2.34 (3H, s, H-12); 
13C NMR (125.76 MHz, CDCl3): δ 169.28 (C-11), 150.88 
(C-2), 139.05 (C-1), 138.00 (C-4), 137.06 (C-9), 122.53 (C-
6), 120.69 (C-5), 116.19 (C-10), 112.73 (C-3), 55.84 (C-7), 
40.12 (C-8), 20.71 (C-12). Physical and spectroscopic data 
were in accordance with those reported.37,38
Eugenyl Propanoate (3b)
Chromatographic purification gave yellowish oil. 
C13H16O3 (M = 220.26); yield 89%; MS (EI): m/z (%) 220 
(M+), 165 (16.52), 164 (100), 149 (23.02), 133 (12.01), 132 
(9.11), 131 (13.91), 104 (10.11), 103 (10.51), 91 (13.21), 57 
(14.01); RI (HP5-MS): 1635; 1H NMR (500.13 MHz, 
CDCl3): δ 6.98 (1H, d, J = 8 Hz, H-6), 6.70–6.90 (2H, m, 
H-3 and H-5), 5.90–6.07 (1H, m, H-9), 5.04–5.23 (2H, m, 
H-10), 3.84 (3H, s, H-7), 3.41 (2H, d, J = 6 Hz, H-8), 2.64 
(2H, q, J = 8 Hz, H-12), 1.31 (3H, t, J = 7 Hz, H-13); 13C 
NMR (125.76 MHz, CDCl3): δ 172.72 (C-11), 150.96 (C-
2), 138.87 (C-1), 138.13 (C-4), 137.13 (C-9), 122.55 (C-6), 
120.68 (C-5), 116.14 (C-10), 112.75 (C-3), 55.84 (C-7), 
40.12 (C-8), 27.39 (C-12), 9.23 (C-13). Physical and spec-
troscopic data were in accordance with those reported.37,38
Eugenyl Butanoate (3c)
Chromatographic purification gave colorless oil. 
C14H18O3 (M = 234.29); yield 87%; MS (EI): m/z (%) 234 
(M+), 165 (10.91), 164 (100), 149 (19.02), 133 (10.01), 132 
(7.91), 131 (11.21), 104 (8.21), 103 (8.41), 91 (10.31), 43 
(8.41); RI (HP5-MS): 1729; 1H NMR (500.13 MHz, 
CDCl3): δ 6.97 (1H, d, J = 8 Hz, H-6), 6.77–6.84 (2H, m, 
H-3 and H-5), 5.94–6.04 (1H, m, H-9), 5.09–5.17 (2H, m, 
H-10), 3.83 (3H, s, H-7), 3.41 (2H, d, J = 6 Hz, H-8), 2.59 
(2H, t, J = 7 Hz, H-12), 1.83 (2H, spt, J = 7 Hz, H-13), 1.08 
(3H, t, J = 7 Hz, H-14); 13C NMR (125.76 MHz, CDCl3): δ 
171.89 (C-11), 150.93 (C-2), 138.87 (C-1), 138.09 (C-4), 
137.13 (C-9), 122.57 (C-6), 120.68 (C-5), 116.13 (C-10), 
112.73 (C-3), 55.81 (C-7), 40.12 (C-8), 35.94 (C-12), 18.62 
(C-13), 13.62 (C-14). Physical and spectroscopic data were 
in accordance with those reported.11,38
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Eugenyl 2-Methylpropanoate (3d)
Chromatographic purification gave colorless oil. 
C14H18O3 (M = 234.29); yield 76%; MS (EI): m/z (%) 234 
(M+), 165 (11.11), 164 (100), 149 (16.72), 133 (8.71), 131 
(10.01), 103 (8.71), 91 (10.61), 77 (7.71), 71 (7.81), 43 
(8.41); RI (HP5-MS): 1679; 1H NMR (500.13 MHz, 
CDCl3): δ 6.94–7.03 (1H, m, H-6), 6.77–6.82 (2H, m, H-3 
and H-5), 5.95–6.03 (1H, m, H-9), 5.10–5.16 (2H, m, 
H-10), 3.83 (3H, s, H-7), 3.41 (2H, d, J = 6.24 Hz, H-8), 
2.86 (2H, spt, J = 6.9 Hz, H-12), 1.35 (6H, d, J = 6.9 Hz, 2 × 
CH3: H-13 and H-14); 13C NMR (125.76 MHz, CDCl3): δ 
175.40 (C-11), 150.97 (C-2), 138.76 (C-1), 138.25 (C-4), 
137.16 (C-9), 122.49 (C-6), 120.68 (C-5), 116.08 (C-10), 
112.80 (C-3), 55.87 (C-7), 40.11 (C-8), 34.00 (C-12), 19.08 
(2 × CH3: C-13 and C-14). Physical and spectroscopic data 
were in accordance with those reported.33,44
Eugenyl Pentanoate (3e)
Chromatographic purification gave colorless oil. 
C15H20O3 (M = 248.32); yield 85%; MS (EI): m/z (%) 248 
(M+), 165 (11.01), 164 (100), 149 (15.82), 133 (8.81), 131 
(9.61), 104 (7.41), 103 (7.51), 91 (9.31), 57 (14.61), 55 
(6.71); RI (HP5-MS): 1829; 1H NMR (500.13 MHz, 
CDCl3): δ 6.96 (1H, d, J = 8 Hz, H-6), 6.76–6.83 (2H, m, 
H-3 and H-5), 5.94–6.03 (1H, m, H-9), 5.09–5.16 (2H, m, 
H-10), 3.83 (3H, s, H-7), 3.40 (2H, d, J = 6 Hz, H-8), 2.60 
(2H, t, J = 8 Hz, H-12), 1.78 (2H, quin, J = 7 Hz, H-13), 
1.49 (2H, sxt, J = 7 Hz, H-14), 1.0 (3H, t, J = 7 Hz, H-15); 
13C NMR (125.76 MHz, CDCl3): δ 172.07 (C-11), 150.93 
(C-2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-9), 122.55 (C-
6), 120.68 (C-5), 116.13 (C-10), 112.73 (C-3), 55.81 (C-7), 
40.11 (C-8), 33.79 (C-12), 27.13 (C-13), 22.22 (C-14), 
13.76 (C-15). Physical and spectroscopic data were in ac-
cordance with those reported.11,38
Eugenyl 3-Methylbutanoate (3f)
Chromatographic purification gave colorless oil. 
C15H20O3 (M = 248.32); yield 85%; MS (EI): m/z (%) 248 
(M+) (3.20), 165 (11.41), 164 (100), 149 (15.72), 133 (7.41), 
132 (6.81), 121 (2.90); RI (HP5-MS): 1785; 1H NMR 
(500.13 MHz, CDCl3): δ 6.96 (1H, d, J = 6.3 Hz, H-6), 
6.78–6.82 (2H, m, H-3 and H-5), 5.98 (1H, s, H-9), 5.10–
5.16 (2H, m, H-10), 3.83 (3H, s, H-7), 3.41 (2H, d, J = 6.24 
Hz, H-8), 2.48 (2H, d, J = 7.63 Hz, H-12), 2.29 (1H, m, 
H-13), 1.10 (6H, d, J = 6.24 Hz, 2 × CH3: H-14 and H-15); 
13C NMR (125.76 MHz, CDCl3): δ 171.26 (C-11), 150.94 
(C-2), 138.87 (C-1), 138.08 (C-4), 137.13 (C-9), 122.57 (C-
6), 120.68 (C-5), 116.11 (C-10), 112.75 (C-3), 55.75 (C-7), 
43.14 (C-12), 40.11 (C-8), 25.97 (C-13), 22.39 (2 × CH3: 
C-14 and C-15). Physical and spectroscopic data were in 
accordance with those reported.33
Eugenyl Hexanoate (3g) 
Chromatographic purification gave colorless oil. 
C16H22O3 (M = 262.34); yield 82%; MS (EI): m/z (%) 262 
(M+), 165 (10.71), 164 (100), 149 (13.31), 133 (7.11), 132 
(6.11), 103 (6.71), 91 (7.91), 55 (6.81), 43 (8.71); RI (HP5-
MS): 1932; 1H NMR (500.13 MHz, CDCl3): δ 6.94 (1H, d, 
J = 8 Hz, H-6), 6.72–6.83 (2H, m, H-3 and H-5), 5.90–6.03 
(1H, m, H-9), 5.05–5.17 (2H, m, H-10), 3.82 (3H, s, H-7), 
3.39 (d, J = 6.6 Hz, 2H, H-8), 2.59 (2H, t, J = 7.5 Hz, H-12), 
1.76 (2H, quin, J = 7.5 Hz, H-13), 1.47 (2H, sxt, J = 7.5 Hz, 
H-15), 0.98 (3H, t, J = 7.5 Hz, H-16); 13C NMR (125.76 
MHz, CDCl3): δ 172.01 (C-11), 150.87 (C-2), 138.80 (C-
1), 138.05 (C-4), 137.06 (C-9), 122.50 (C-6), 120.62 (C-5), 
116.07 (C-10), 112.69 (C-3), 55.76 (C-7), 40.06 (C-8), 
33.75 (C-12), 27.08 (C-13), 22.47 (C-14), 22.37 (C-15), 
13.98 (C-16). Physical and spectroscopic data were in ac-
cordance with those reported.38
Eugenyl Heptanoate (3h)
Chromatographic purification gave colorless oil. 
C17H24O3 (M = 276.37); yield 82%; MS (EI): m/z (%) 276 
(M+), 165 (11.31), 164 (100), 149 (11.71), 133 (6.01), 132 
(5.21), 131 (6.61), 103 (4.90), 91 (6.01), 55 (5.91), 43 (6.51); 
RI (HP5-MS): 2037; 1H NMR (500.13 MHz, CDCl3): δ 
6.96 (1H, d, J = 8 Hz, H-6), 6.76–6.83 (2H, m, H-3 and 
H-5), 5.94–6.03 (1H, m, H-9), 5.09–5.16 (2H, m, H-10), 
3.83 (3H, s, C-7), 3.40 (2H, d, J = 7 Hz, H-8), 2.60 (2H, t, J 
= 7 Hz, H-12), 1.78 (2H, quin, J = 7 Hz, H-13), 1.46 (2H, 
bs, H-14), 1.31–1.42 (4H, m, H-15 and H-16), 0.94 (3H, 
bs, H-17); 13C NMR (125.76 MHz, CDCl3): δ 172.08 (C-
11), 150.93 (C-2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-
9), 122.55 (C-6), 120.68 (C-5), 116.13 (C-10), 112.73 (C-
3), 55.81 (C-7), 40.12 (C-8), 34.10 (C-12), 31.49 (C-15), 
28.75 (C-14), 25.05 (C-13), 22.55 (C-16), 14.06 (C-17). 
Physical and spectroscopic data were in accordance with 
those reported.38
Eugenyl Octanoate (3i)
Chromatographic purification gave yellowish oil. 
C18H26O3 (M = 290.40); yield 86%; MS (EI): m/z (%) 290 
(M+), 165 (16.52), 164 (100), 149 (10.31), 133 (5.41), 132 
(4.60), 131 (5.81), 103 (4.60), 91 (5.21), 57 (10.21), 55 
(7.71); RI (HP5-MS): 2141; 1H NMR (500.13 MHz, 
CDCl3): δ 6.96 (1H, d, J = 8.3 Hz, H-6), 6.76–6.83 (2H, m, 
H-3 and H-5), 5.94–6.03 (1H, m, H-9), 5.09–5.18 (2H, m, 
H-10), 3.83 (3H, s, C-7), 3.40 (2H, d, J = 6.2 Hz, H-8), 2.59 
(2H, t, J = 7.3 Hz, H-12), 1.79 (2H, quin, J = 7.3 Hz, H-13), 
1.28–1.49 (8H, bm, H-14–H-17), 0.88–0.97 (3H, m, 
H-18); 13C NMR (125.76 MHz, CDCl3): δ 172.08 (C-11), 
150.93 (C-2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-9), 
122.57 (C-6), 120.68 (C-5), 116.13 (C-10), 112.73 (C-3), 
55.81 (C-7), 40.12 (C-8), 34.10 (C-12), 31.73 (C-16), 29.05 
(C-15), 28.97 (C-14), 25.10 (C-13), 22.64 (C-17), 14.11 
(C-18). Physical and spectroscopic data were in accor-
dance with those reported.38
Eugenyl Nonanoate (3j)
Chromatographic purification gave yellowish oil. 
C19H28O3 (M = 304.42); yield 76%; MS (EI): m/z (%) 304 
(M+), 165 (11.31), 164 (100), 149 (9.01), 137 (1.90), 133 
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(4.40), 132 (4.60), 131 (3.10), 121 (1.50), 107 (1.30), 104 
(2.00); RI (HP5-MS): 2246; 1H NMR (500.13 MHz, 
CDCl3): δ 6.96 (1H, d, J = 8.3 Hz, H-6), 6.70–6.84 (2H, m, 
H-3 and H-5), 5.92–6.04 (1H, m, H-9), 5.03–5.18 (2H, m, 
H-10), 3.83 (3H, s, C-7), 3.40 (2H, d, J = 6.2 Hz, H-8), 2.59 
(2H, t, J = 7.3 Hz, H-12), 1.78 (2H, quin, J = 7.5 Hz, H-13), 
1.29–1.49 (10H, bm, H-14–H-18), 0.83–1.06 (3H, m, 
H-19); 13C NMR (125.76 MHz, CDCl3): δ 172.08 (C-11), 
150.93 (C-2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-9), 
122.57 (C-6), 120.68 (C-5), 116.13 (C-10), 112.73 (C-3), 
55.81 (C-7), 40.11 (C-8), 34.10 (C-12), 31.84 (C-17), 29.27 
(C-16), 29.19 (C-15), 29.10 (C-14), 25.09 (C-13), 22.68 
(C-18), 14.13 (C-19). Physical and spectroscopic data were 
in accordance with those reported.38
Eugenyl Decanoate (3k)
Chromatographic purification gave colorless oil. 
C20H30O3 (M = 318.45); yield 85%; MS (EI): m/z (%) 318 
(M+), 166 (1.00), 165 (11.31), 164 (100), 149 (7.91), 147 
(1.00), 137 (1.70), 133 (4.40), 105 (1.50), 103 (4.00); 85 
(1.40); RI (HP5-MS): 2348; 1H NMR (500.13 MHz, CDCl3): 
δ 6.96 (1H, d, J = 7.6 Hz, H-6), 6.78–6.82 (2H, m, H-3 and 
H-5), 5.95–6.04 (1H, m, H-9), 5.10–5.17 (2H, m, H-10), 
3.83 (3H, s, C-7), 3.40 (2H, d, J = 6.2 Hz, H-8), 2.59 (2H, t, 
J = 7.6 Hz, H-12), 1.79 (2H, quin, J = 7.6 Hz, H-13), 1.27–
1.48 (12H, bm, H-14–H-19), 0.92 (3H, t, J = 6.9 Hz, H-20); 
13C NMR (125.76 MHz, CDCl3): δ 172.08 (C-11), 150.93 
(C-2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-9), 122.57 (C-
6), 120.68 (C-5), 116.13 (C-10), 112.73 (C-3), 55.81 (C-7), 
40.12 (C-8), 34.10 (C-12), 31.91 (C-18), 29.5 (C-16), 29.32 
(2 × CH2: C-15 and C-17), 29.10 (C-14), 25.10 (C-13), 
22.71 (C-19), 14.14 (C-20). Physical and spectroscopic 
data were in accordance with those reported.38
Eugenyl Undecanaote (3l)
Chromatographic purification gave colorless oil. 
C21H32O3 (M = 332.48); yield 87%; MS (EI): m/z (%) 332 
(M+), 165 (11.21), 164 (100), 149 (7.31), 133 (3.90), 131 
(4.50), 103 (3.70), 91 (4.30), 57 (5.91), 55 (10.01); RI (HP5-
MS): 2449; 1H NMR (500.13 MHz, CDCl3): δ 6.96 (1H, d, 
J = 8.3 Hz, H-6), 6.78–6.82 (2H, m, H-3 and H-5), 5.95–
6.03 (1H, m, H-9), 5.10–5.16 (2H, m, H-10), 3.83 (3H, s, 
C-7), 3.40 (2H, d, J = 6.24 Hz, H-8), 2.59 (2H, t, J = 7.28 
Hz, H-12), 1.78 (2H, quin, J = 7.28 Hz, H-13), 1.28–1.45 
(14H, bm, H-14–H-20), 0.92 (3H, t, J = 6.6 Hz, H-21); 13C 
NMR (125.76 MHz, CDCl3): δ 172.08 (C-11), 150.93 (C-
2), 138.86 (C-1), 138.09 (C-4), 137.13 (C-9), 122.55 (C-6), 
120.68 (C-5), 116.13 (C-10), 112.73 (C-3), 55.81 (C-7), 
40.12 (C-8), 34.10 (C-12), 31.94 (C-19), 29.61 (C-16), 
29.54 (C-17), 29.35 (C-15), 29.32 (C-18), 29.10 (C-14), 
25.10 (C-13), 22.72 (C-20), 14.14 (C-21).
Eugenyl Dodecanaote (3m)
Chromatographic purification gave colorless oil. 
C22H34O3 (M = 346.50); yield 84%; MS (EI): m/z (%) 346 
(M+), 165 (11.31), 164 (100), 149 (6.41), 133 (3.40), 131 
(3.90), 103 (3.10), 91 (3.20), 57 (5.01), 55 (8.51); RI (HP5-
MS): 2553; 1H NMR (500.13 MHz, CDCl3): δ 6.96 (1H, d, J 
= 8.3 Hz, H-6), 6.77–6.82 (2H, m, H-3 and H-5), 5.95–6.03 
(1H, m, H-9), 5.10–5.16 (2H, m, H-10), 3.83 (3H, s, C-7), 
3.40 (2H, d, J = 6.9 Hz, H-8), 2.59 (2H, t, J = 7.28 Hz, H-12), 
1.78 (2H, quin, J = 7.6 Hz, H-13), 1.28–1.51 (16H, bm, 
H-14–H-21), 0.92 (3H, t, J = 6.6 Hz, H-22); 13C NMR 
(125.76 MHz, CDCl3): δ 172.08 (C-11), 150.93 (C-2), 138.86 
(C-1), 138.09 (C-4), 137.13 (C-9), 122.55 (C-6), 120.68 (C-
5), 116.13 (C-10), 112.72 (C-3), 55.79 (C-7), 40.12 (C-8), 
34.10 (C-12), 31.94 (C-20), 29.65 (2 × CH2: C-16 and C-18), 
29.54 (C-17), 29.37 (C-15), 29.32 (C-19), 29.10 (C-14), 
25.10 (C-13), 22.72 (C-21), 14.14 (C-22). Physical and spec-
troscopic data were in accordance with those reported.18,38
Eugenyl Tridecanaote (3n)
Chromatographic purification gave yellowish oil. 
C23H36O3 (M = 360.53); yield 87%; MS (EI): m/z (%) 360 
(M+), 164 (100), 149 (6.51), 131 (3.10), 103 (3.10), 91 
(3.11), 57 (5.10), 55 (8.40); RI (HP5-MS): 2655; 1H NMR 
(500.13 MHz, CDCl3): δ 6.97 (1H, d, J = 8.3 Hz, H-6), 
6.78–6.82 (2H, m, H-3 and H-5), 5.95–6.04 (1H, m, H-9), 
5.10–5.16 (2H, m, H-10), 3.83 (3H, s, C-7), 3.40 (2H, d, J = 
6.94 Hz, H-8), 2.60 (2H, t, J = 7.28 Hz, H-12), 1.78 (2H, 
quin, J = 7.3 Hz, H-13), 1.27–1.54 (16H, bm, H-14–H-22), 
0.92 (3H, t, J = 6.6 Hz, H-23); 13C NMR (125.76 MHz, 
CDCl3): δ 172.04 (C-11), 150.94 (C-2), 138.84 (C-1), 
138.13 (C-4), 137.13 (C-9), 122.57 (C-6), 120.68 (C-5), 
116.13 (C-10), 112.75 (C-3), 55.79 (C-7), 40.12 (C-8), 
34.10 (C-12), 31.95 (C-21), 29.38–29.70 (4 × CH2: C-16 - 
C-19), 29.32 (2 × CH2: C-15 and C-20), 29.10 (C-14), 
25.10 (C-13), 22.72 (C-22), 14.14 (C-23).
Eugenyl Tetradecanoate (3o)
Chromatographic purification gave yellowish oil. 
C24H38O3 (M = 374.56); yield 79%; MS (EI): m/z (%) 374 
(M+), 165 (13.01), 164 (100), 149 (5.81), 133 (3.10), 132 
(2.80), 131 (3.50), 69 (2.50), 57 (3.60), 55 (5.51), 43 (2.50); 
RI (HP5-MS): 2753; 1H NMR (500.13 MHz, CDCl3): δ 6.97 
(1H, d, J = 8.32 Hz, H-6), 6.78–6.83 (2H, m, H-3 and H-5), 
5.95–6.04 (1H, m, H-9), 5.10–5.17 (2H, m, H-10), 3.83 
(3H, s, C-7), 3.41 (2H, d, J = 6.24 Hz, H-8), 2.60 (2H, t, J = 
7.63 Hz, H-12), 1.78 (2H, m, H-13), 1.27–1.50 (18H, bm, 
H-14–H-23), 0.97–0.88 (3H, m, H-24); 13C NMR (125.76 
MHz, CDCl3): δ 171.97 (C-11), 150.97 (C-2), 138.81 (C-1), 
138.16 (C-4), 137.11 (C-9), 122.57 (C-6), 120.66 (C-5), 
116.08 (C-10), 112.73 (C-3), 55.76 (C-7), 40.12 (C-8), 34.08 
(C-12), 31.97 (C-22), 29.56–29.72 (5 × CH2: C-16–C-20), 
29.71 (C-18), 29.67 (C-20), 29.62 (C-17), 29.56 (C-19), 
29.42 (C-22), 29.34 (C-15), 29.11 (C-14), 25.12 (C-13), 
22.74 (C-23), 14.14 (C-24). Physical and spectroscopic data 
were in accordance with those reported.18
Eugenyl Pentadecanoate (3p)
Chromatographic purification gave colorless oil. 
C25H40O3 (M = 388.58); yield 89%; MS (EI): m/z (%) 388 
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(M+), 165 (10.91), 164 (100), 149 (5.61), 131 (3.70), 69 
(5.51), 57 (8.41), 55 (14.11), 43 (9.31), 41 (4.10); RI (HP5-
MS): 2858; 1H NMR (500.13 MHz, CDCl3): δ 6.97 (1H, d, 
J = 8.32 Hz, H-6), 6.78–6.83 (2H, m, H-3 and H-5), 5.95–
6.04 (1H, m, H-9), 5.10–5.17 (2H, m, H-10), 3.83 (3H, s, 
C-7), 3.41 (2H, d, J = 6.24 Hz, H-8), 2.60 (2H, t, J = 7.63 
Hz, H-12), 1.78 (2H, m, H-13), 1.27–1.50 (18H, bm, 
H-14–H-24), 0.97–0.88 (3H, m, H-25); 13C NMR (125.76 
MHz, CDCl3): δ 172.02 (C-11), 150.96 (C-2), 138.82 (C-
1), 138.16 (C-4), 137.11 (C-9), 122.57 (C-6), 120.68 (C-5), 
116.11 (C-10), 112.75 (C-3), 55.78 (C-7), 40.12 (C-8), 
34.10 (C-12), 31.97 (C-23), 29.56–29.75 (6 × CH2: C-16–
C21), 29.42 (C-22), 29.34 (C-15), 29.11 (C-14), 25.12 (C-
13), 22.74 (C-24), 14.16 (C-25).
Eugenyl Hexadecanoate (3q)
Chromatographic purification gave white solid. M.p. 
39–40 °C. C26H42O3 (M = 402.61); yield 92%; MS (EI): m/z 
(%) 402 (M+), 165 (13.41), 164 (100), 149 (5.31), 133 
(2.70), 132 (2.50), 131 (3.10), 69 (2.60), 57 (3.70), 55 (5.40), 
43 (2.40); RI (HP5-MS): 2976; 1H NMR (500.13 MHz, 
CDCl3): δ 6.96 (1H, d, J = 7.63 Hz, H-6), 6.77–6.82 (2H, m, 
H-3 and H-5), 5.95–6.04 (1H, m, H-9), 5.10–5.16 (2H, m, 
H-10), 3.83 (3H, s, C-7), 3.40 (2H, d, J = 6.24 Hz, H-8), 
2.60 (2H, t, J = 7.60 Hz, H-12), 1.79 (2H, quin, J = 7.50 Hz, 
H-13), 1.27–1.48 (20H, bm, H-14–H-25), 0.95–0.85 (3H, 
m, H-26); 13C NMR (125.76 MHz, CDCl3): δ 172.07 (C-
11), 150.94 (C-2), 138.84 (C-1), 138.11 (C-4), 137.11 (C-
9), 122.55 (C-6), 120.68 (C-5), 116.11 (C-10), 112.73 (C-
3), 55.81 (C-7), 40.11 (C-8), 34.10 (C-12), 31.95 (C-24), 
29.54–29.72 (6 × CH2: C-16–C-22), 29.38 (C-23), 29.32 
(C-15), 29.10 (C-14), 25.10 (C-13), 22.71 (C-25), 14.14 
(C-26). Physical and spectroscopic data were in accor-
dance with those reported.18,38
Eugenyl Heptadecanoate (3r)
Chromatographic purification gave yellowish solid. 
M.p. 49–50 °C. C27H44O3 (M = 416.64); yield 76%; MS (EI): 
m/z (%) 416 (M+), 165 (12.11), 164 (100), 149 (4.60), 133 
(2.50), 132 (2.10), 131 (2.80), 69 (3.00), 57 (4.20), 55 (6.00), 
43 (3.00); RI (HP5-MS): 3096; 1H NMR (500.13 MHz, 
CDCl3): δ 6.97 (1H, d, J = 8 Hz, H-6), 6.74–6.88 (2H, m, 
H-3 and H-5), 5.95–6.05 (1H, m, H-9), 5.04–5.22 (2H, m, 
H-10), 3.84 (3H, s, C-7), 3.42 (2H, d, J = 7.0 Hz, H-8), 2.60 
(2H, t, J = 7.0 Hz, H-12), 1.81 (2H, quin, J = 7.0 Hz, H-13), 
1.28–1.51 (22H, bm, H-14–H-26), 0.94 (3H, t, J = 7.0 Hz, 
H-27); 13C NMR (125.76 MHz, CDCl3): δ 171.97 (C-11), 
150.97 (C-2), 138.81 (C-1), 138.16 (C-4), 137.11 (C-9), 
122.57 (C-6), 120.66 (C-5), 116.10 (C-10), 112.73 (C-3), 
55.76 (C-7), 40.12 (C-8), 34.10 (C-12), 31.99 (C-25), 29.57–
29.77 (7 × CH2: C-16–C-23), 29.43 (C-24), 29.35 (C-15), 
29.11 (C-14), 25.12 (C-13), 22.75 (C-26), 14.14 (C-27).
Eugenyl Benzoate (3s)
Chromatographic purification gave white solid. M.p. 
70–71 °C. C17H16O3 (M = 268.31); yield 96%; MS (EI): m/z 
(%) 268 (M+) (20.82), 269 (3.80), 106 (9.61), 105 (100), 91 
(5.41), 78 (3.10), 77 (33.93), 65 (1.90), 51 (4.60); RI (HP5-
MS): 2170; 1H NMR (500.13 MHz, CDCl3): δ 8.25 (2H, d, 
J = 8.32 Hz, H-2’ and H-6’), 7.66 (1H, t, J = 7.28 Hz, H-4’), 
7.53 (2H, t, J = 7.63 Hz, H-3’ and H-5’), 7.10 (1H, d, J = 
8.32 Hz, H-6), 6.87 (1H, s, H-3), 6.85 (1H, d, J = 8.32 Hz, 
H-5), 5.98–6.06 (1H, m, H-9), 5.12–5.18 (2H, m, H-10), 
3.83 (3H, s, H-7), 3.44 (2H, d, J = 6.94 Hz, H-8); 13C NMR 
(125.76 MHz, CDCl3): δ 164.91 (C-11), 151.13 (C-2), 
139.08 (C-4), 138.22 (C-9), 137.14 (C-1)), 133.42 (C-4’), 
130.32 (C-2’ and C-6’), 129.55 (C-1’), 128.51 (2 × ArC: 
C-3’ and C-5’), 122.68 (C-5), 120.76 (C-6), 116.17 (C-10), 
112.88 (C-3), 55.90 (C-7), 40.15 (C-8). Physical and spec-
troscopic data were in accordance with those reported.11,37
2. 3. Identification of Synthetized Compounds
2. 3. 1. GC-MS Analysis
MS spectra of samples of the synthesized compounds 
were recorded on a 7890/7000B GC/MS/MS triple quad-
rupole system (Agilent Technologies, USA, equipped with 
a Combi PAL auto sampler). The fused silica capillary col-
umn HP-5MS (5% phenylmethylsiloxane, 30 m × 0.25 
mm, film thickness 0.25 μm, Agilent Technologies, Palo 
Alto, CA, USA) was used. The injector, source and inter-
face operated at 250, 230 and 300 °C, respectively. The 
temperature program: from 60 for 5 min isothermal to 300 
°C at a heating rate of 8 °C/min and on 300 °C for 5 min 
isothermal. The solutions in hexane were injected in split 
ratio 10:1. The carrier gas was helium with a flow of 1.0 
mL/min. Post run: back flash for 1.89 min, at 280 °C, with 
helium at 50 psi. MS conditions were as follows: ionization 
voltage of 70 eV, acquisition mass range 50–650, scan time 
0.32 s. Semi-quantitative analysis was carried out directly 
from peak areas in the GC profile.
Linear retention indices (RI) were determined based 
on the retention times of C8–C40 alkanes run on HP-5MS 
column using the above mentioned temperature pro-
gramme.45
2. 3. 2. NMR Analysis
NMR spectra were registered on a Bruker AVANCE 
500 spectrometer equipped with a 5 mm broadband re-
verse probe with field z-gradient operating at 500.13 and 
125.76 MHz for 1H and 13C, respectively. All NMR spectra 
were recorded at 298 K in CDCl3 (isotopic enrichment 
99.95%) solution. Chemical shifts are reported on the δ 
(ppm) scale and are relative to residual CHCl3 signals (7.24 
for 1H and 77.0 ppm, central line, for 13C spectra respec-
tively), and scalar coupling constants are reported in hertz. 
The experimental error in the measured 1H–1H coupling 
constants was ± 0.5 Hz.
The signals assignment was given by a combination 
of 1D and 2D COSY and HSQC experiments, using stan-
dard Bruker pulse programs. 
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Acquisition parameters for 1D were as follows: 1H 
spectral width of 5000 Hz and 32 K data points providing 
a digital resolution of ca. 0.305 Hz per point, relaxation 
delay 2 s; 13C spectral width of 29412 Hz and 64 K data 
points providing a digital resolution of ca. 0.898 Hz per 
point, relaxation delay 2.5 s. The experiments were per-
formed through standard pulse sequences. gCOSY-45 ex-
periments were acquired with 512 t1 increments; 2048 t2 
points; spectral/spectrum width 10.0 ppm. The acquisition 
data for gHSQC and gHMBC experiments were obtained 
with 512 t1 increments; 2048 t2 points; spectral/spectrum 
width 10.0 ppm for 1H and 220 ppm for 13C. Delay values 
were optimized for 1JC,H 140.0 Hz and nJC,H 3.0 Hz. Zero 
filling in F1 to 1 K, p/2 shifted sine-bell squared (for 
gHSQC) or sinebell (for gHMBC) apodization functions 
were used for processing.
2. 4. Antimicrobial Activity
2. 4. 1. Microbial Strains
The in vitro antimicrobial activity of the synthesized 
compounds was tested against a panel of laboratory con-
trol strains belonging to the American Type Culture Col-
lection Maryland, USA: Gram-positive: Bacillus subtilis 
ATCC 6633 and Staphylococcus aureus ATCC 6538; 
Gram-negative: Escherichia coli ATCC 8739, fungal organ-
isms: Aspergillus niger ATCC 16404 and Candida albicans 
ATCC 10231. The Gram-negative bacteria Salmonella abo-
ny NCTC 6017 and Salmonela typhimurium ATCC 14028 
were obtained from the National Collection of Type Cul-
tures. All microorganisms were maintained at –20 ºC un-
der appropriate conditions and regenerated twice before 
use in the manipulations.
2. 4. 2. Screening of Antimicrobial Activity
The minimal inhibitory concentration (MIC) of es-
ters was determined based on a broth microdilution meth-
od in 96-well microtitre plates.46 The inocula of the bacte-
rial strains were prepared from overnight broth cultures 
and suspensions were adjusted to 0.5 McFarland standard 
turbidity. Dimethyl sulphoxide (10% aqueous solution) 
was used to dissolve and to dilute samples to the highest 
concentration to be tested (stock concentrations 2 mg/
mL). A serial doubling dilution of the samples was pre-
pared in a 96-well microtiter plate, using the method of 
Sarker et al.47 with slight modifications. The minimal bac-
tericidal/fungicidal concentration (MBC/MFC) was eval-
uated as the lowest concentration of tested samples at 
which inoculated microorganisms were 99.9% killed. Tests 
were carried out in triplicate.
2. 5.  In silico Physico-chemical, Pharmacokinetic 
and Toxicological Properties of the 
Synthetized Compounds
In order to obtain a complete picture of the synthe-
sized compounds (3a–s) an in silico study was performed. 
Physico-chemical, pharmacokinetic and toxicological 
properties of compounds were calculated using the Molin-
spiration,48 admetSAR,49 DataWarrior50 and Toxtree51 pre-
diction tools.
3. Results and Discussion
3. 1. Chemical Synthesis
A small focused library of nineteen eugenyl esters 
was synthesized. To the best of our knowledge four out of 
nineteen compounds are new (3l, 3n, 3p and 3r; Scheme 
1). All compounds were synthesized according to previ-
ously published standard methodology and with high 
yields ranging from 76% to 96% (Table 1).
3. 2. Antimicrobial Activity
The results obtained in broth microdilution assay are 
given in Table 2. The assayed samples were less effective 
than antibiotic/antimycotic used as reference standard and 
if noted, activity was never greater than the values ob-
tained for the parent compound 1 (MIC/MBC/MFC never 
exceeded 0.5 mg/mL, Table 2). The results are indicating 
selective susceptibility of the microorganisms, with B. sub-
tilis (3d, 3l, 3n–r), S. aureus (3e and 3f), A. niger (3f, 3s) 
Scheme 1. Synthesis of eugenyl esters
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and C. albicans (3d, 3f, 3n, 3n and 3s) being the most sen-
sitive strains on the synthesized derivatives. On the other 
hand, all three Gram-negative microorganisms tested (E. 
coli, S. abony and S. typhimurium) were completely resis-
tant to synthesized compounds tested (initial concentra-
tion 2 mg/mL).
Four of our samples (3a, 3e, 3f, 3s) are matching the 
samples tested in antibacterial assays so far.29–31 Eugenyl 
acetate (3a) was tested in a disc diffusion method on a set 
of seven Gram-positive and nine Gram-negative bacte-
ria.30 The results have shown notable antimicrobial effect 
against all sixteen bacteria tested, with a superior perfor-
mance when compared to pure eugenol.30 Even when dif-
ferent methodologies were employed, two crucial and 
completely opposed observations can be made; our results 
have shown that derivatives have never exceeded the activ-
ity of the parent compound and that all were inactive 
against Gram-negative bacteria taken into consideration. 
Eugenyl benzoate (3s) was tested previously in disc diffu-
sion assay against a smaller panel of laboratory controlled 
bacterial strains (two Gram-positive, two Gram-nagative). 
Table 1. Eugenyl esters: chemical entity, yields (%) and entry
R Yield (%) Entry 
CH3 96 3a
CH2CH3 89 3b
CH2CH2CH3 87 3c
CH(CH3)2 76 3d
CH2(CH2)2CH3 85 3e
CH2CH(CH3)2 85 3f
CH2(CH2)3CH3 82 3g
CH2(CH2)4CH3 82 3h
CH2(CH2)5CH3 86 3i
CH2(CH2)6CH3 76. 3j
CH2(CH2)7CH3 85 3k
CH2(CH2)8CH3 87 3l
CH2(CH2)9CH3 84 3m
CH2(CH2)10CH3 87 3n
CH2(CH2)11CH3 79 3o
CH2(CH2)12CH3 89 3p
CH2(CH2)13CH3 92 3q
CH2(CH2)14CH3 76 3r
Ph 96 3s
Table 2. The minimal inhibitory (MIC) and minimal bactericidal/fungicidal (MBC/MFC) concentrations (mg/mL) of the eugenol (1) and the synthetized 
eugenyl esters 3a–s. MIC and MBC/MFC determinations were carried out in triplicate and consistent values were obtained for each microorganism tested.
                                     Bacterial strains                                     Fungal strains
                       Gram-positive   Gram-negative 
Cmpd. B. subtilis S. aureus E. coli S. abony S. typhimurium A. niger C. albicans
1 MIC = 0.5 MIC =  MIC = 0.5 MIC = 0.5 MIC =  MIC =  MIC = 0.25
  MBC = 0.5 MBC = 1.0 MBC = 1.0 MBC = 0.5 MFC = 0.5 MFC = 1.0
3a na na na na na na MIC = 
       MFC = 0.5
3b na na na na na na na
3c na na na na na na na
3d MIC = 0.5 na na na na na MIC= 0.5
3e na na na na na na na
3f na MIC = 0.5 na na na MIC = 0.5 MIC = 0.5
3g na na na na na na na
3h na na na na na na na
3i na na na na na na na
3j na na na na na na na
3k na na na na na na na
3l MIC = 1.0 na na na na na na
3m na na na na na na na
3n MIC = 0.5 na na na na na MIC = 0.5
3o MIC = 1.0 na na na na na na
3p MIC = 0.5 na na na na na na
3q MIC = 0.5 na na na na na na
3r MIC = 0.5 na na na na na MIC = 1.0
3s na na na na na MIC = 1.0 MIC = 1.0
Doxycycline MIC =  MIC = 6.25 MIC =  MIC =  MIC = 6.25 nt nt
(μg/mL) MBC = 1.56 MBC = 0.78 MBC = 0.78 MBC = 6.25 MBC > 50
Nystatin nt nt nt nt nt MIC =  MIC = 
(μg/mL)      MBC = 6.25 MBC = 0.78
DMSO 10%   na na na na na na na
aqueous 
solution
na, not active; nt, not tested
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Stronger antibacterial activity of benzoate was observed 
compared to its unsubstituted analogue, i.e. eugenol.29 
Eugenyl pentanoate (3e) and 3-methylbutanoate (3f) were 
tested against seventeen different bacterial strains (ATTC, 
clinical or food isolates) and have shown moderate anti-
bacterial potential, with inhibitory values (MIC) ranging 
from 0.32 to 6.00 mg/mL.31 No noticeable difference in the 
susceptibility of Gram-negative and Gram-positive bacte-
ria was observed.31 For the rest of the synthesized com-
pounds (3b–d, 3g–r) antibacterial results are reported 
here for the first time. For all compounds synthetized (3a–
s) results obtained for antifungal assay are the first ever 
reported (Table 2).
3. 3. In silico Study
3. 3. 1.  Physico-chemical Properties of the Eugenyl 
Esters 3a–s
Lipinski’s rule of five has been used to evaluate drug 
likeness and to determine if a pharmacologically or bio-
logically active compound has properties that would make 
it a likely orally active drug in humans. In our previously 
published paper we have already summarized factors im-
portant for optimal bioavailability of synthesized com-
pounds.52 According to the physico-chemical properties 
calculated by Molinspiration software tool,48 compounds 
3a–h and 3s fulfilled all requirements for good oral bio-
availability, including miLogP < 5, nON < 10, nOHNH < 5, 
MW < 500, TPSA < 140 Å2 (< 60 Å2), and nrotb < 10 (Suple-
mentary data, Table S1). 
3. 3. 2.  Pharmacokinetic Properties of the Eugenyl 
Esters 3a–s
Absorption properties of compounds 3a–s were pre-
dicted by admetSAR49 (Supplementary data, Table S2). 
Based on the results, all of the studied compounds were 
predicted as compounds able to pass through blood-brain 
barrier and penetrate into the central nervous system, as 
compounds capable of being absorbed by intestine, as well 
as compounds permeable across Caco-2 cells. Compounds 
3g–r were predicted as P-glycoprotein substrates, while 
compound 3s was predicted as P-glycoprotein inhibitor. 
None of the studied compounds was predicted as inhibitor 
of renal organic cation transporter.
Metabolic properties of the eugenyl esters 3a–s were 
predicted by admetSAR49 (Supplementary data, Table S3). 
None of the studied compounds was predicted as CYP2C9 
and/or CYP2D6 substrate, while 15 compounds (3c, 3e–r) 
were predicted as CYP3A4 substrate. Regarding CYP450 
inhibition, enzyme CYP1A2 might be inhibited by com-
pounds 3c, 3e–s, CYP2C9 by compound 3s, CYP2C19 by 
compounds 3b, 3c, 3h–s. However, none of the compounds 
was predicted as CYP2D6 inhibitor. Most of the investigat-
ed compounds were predicted to have low CYP 450 inhib-
itory promiscuity, except compounds 3a, 3d and 3s.
3. 3. 3.  Toxicological Properties of the Eugenyl 
Esters 3a–s
Using Toxtree prediction tool based on a decision 
tree approach,51 we have predicted structural alerts for 
DNA and protein binding for the studied compounds. Re-
garding DNA binding alerts, all of the studied compounds 
were predicted to have the ability to undergo nucleophilic 
aliphatic substitution (SN1 reactions) and Michael addi-
tion. Among the protein binding alerts, compounds 3a–s 
were predicted as compounds able to undergo Michael ad-
dition and SN2 reactions; 3a–s were predicted as com-
pounds able to participate in acyl transfer (results given in 
Supplementary data, Tables S4 and S5).
Based on the toxicological properties predicted by 
admetSAR49 compounds 3a–s have been characterized as 
weak hERG (human Ether-à-go-go-Related Gene) inhibi-
tors, non-AMES toxic and non-carcinogenic, but highly 
toxic for fish, Tetrahymena pyriformis and honey bee. Five 
compounds (3a–c, 3e and 3g) were predicted as ready bio-
degradable. According to the risk for acute oral toxicity, all 
of the studied compounds (3a–s) were predicted as Cate-
gory III, or slightly toxic compounds, with LD50 values be-
tween 500 and 5000 mg/kg. Depending on the median 
toxic dose (TD50), all compounds were predicted as 
“non-required” or non-carcinogenic chemicals (Supple-
mentary data, Table S6).
Toxicological properties of the studied compounds 
predicted by DataWarrior50 indicate that all compounds 
have high risk for tumorigenic and irritant effects. All 
compounds were predicted with no risk for mutagenic ef-
fects and no risk for reproductive effects (Supplementary 
data, Table S7).
4. Conclusion
We have synthesized nineteen esters of eugenol, of 
which four represent new compounds (3l, 3n, 3p and 3r). 
All of the compounds were employed in antimicrobial bio-
assay, with several compounds tested for the first time in 
antibacterial (3b–d, 3g–r) and all of the compounds (3a–
s) ever tested in antifungal activity bioassay. The results 
have indicated microorganisms’ selective susceptibility, 
with B. subtilis (3d, 3l, 3n–r), S. aureus (3e and 3f), C. albi-
cans (3d, 3f, 3n, 3r–s) and A. niger (3f, 3s) as the most 
susceptible ones, with minimal inhibitory or cidal concen-
trations (MIC/MBC/MFC) never exceeding the range of 
activity of eugenol as the parent compound. Based on cur-
rent results and on our previously published ones,43 having 
in best case comparable but never greater MIC values than 
for parent phenolic compound we could not confirm re-
sults obtained by previous groups.29–31 Our results have 
shown the importance of free phenolic hydroxyl group in 
terms of activity against microbials, however more de-
tailed research should be conducted involving also a more 
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complex viewpoint, as for instance, the disclosure of 
mechanism of action of eugenyl esters on bacteria and 
fungi. 
The results of our in silico study have shown that com-
pounds fulfilling Lipinski’s rule of five are 3a–h and 3s and 
were predicted to have good oral bioavailability. All of the 
studied compounds were predicted as to be able to pass 
through blood-brain barrier capable of being absorbed by 
intestine and permeable across Caco-2 cells. Metabolic 
properties differ within the studied compounds, depending 
on whether they act as substrate and/or inhibitor of various 
CYP450 enzymes. Compounds 3a–s were predicted as 
weak hERG inhibitors, non-AMES toxic and non-carcino-
genic, but highly toxic for fish, T. pyriformis and honey bee. 
Further, they were predicted as Category III of risk for acute 
oral toxicity, as well as compounds with high risk for tum-
origenic and irritant effects. Finally, they exhibited at least 
two structural alerts for both DNA and protein binding, 
indicating their ability to act as a mutagen or a genotoxic.
Taking in consideration predicted in silico properties 
and estimated drug likeness score, pharmacological and 
toxicological profile, eugenyl esters might be used as prod-
rugs of eugenol due to an expected enhanced lipophilici-
ty53 and passive membrane transport.
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Povzetek
Rezultati, predstavljeni v tem članku, so nadaljevanje naših študij modifikacij molekul naravnega izvora, s posebnim 
poudarkom na aciliranju fenolne funkcionalne skupine. Pripravili smo majhno, fokusirano knjižnico devetnajstih estrov 
evgenola, od katerih so štiri nove spojine. Z vsemi spojinami smo izvedli in vitro antimikrobno testiranje. Z in silico 
računskimi študijami smo napovedali fizikalno-kemijske, farmakokinetične in toksikološke lastnosti, kar daje dodatne 
podatke za boljše usmerjanje raziskav v prihodnosti.
